ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Synthetic Genomics boosts RNA vaccines

by Ryan Cross
November 6, 2017 | APPEARED IN VOLUME 95, ISSUE 44

Synthetic Genomics has formed two partnerships to pursue RNA replicon-based vaccines, in which self-replicating RNA molecules encode multiple antigen proteins to produce an immune response. One partner, Arcturus Therapeutics, will share its RNA delivery system for an undisclosed payment plus milestones and royalties. Arcturus and Janssen recently agreed to develop hepatitis B treatments with the RNA delivery technology. Synthetic Genomics will also partner with Ceva Santé Animale to develop livestock vaccines.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment